Enhanc3D Genomics Appoints Hazel Jones as Chief Executive Officer
15 Mayo 2024 - 3:20AM
Business Wire
Enhanc3D Genomics, a company developing disruptive technologies
to unlock the 3D genome for use in novel target identification and
unique patient stratification, today announced the appointment of
Hazel Jones as Chief Executive Officer, after a successful
six-month tenure as interim CEO and COO.
As COO and interim CEO Hazel has overseen the Company's global
business operations and held responsibility for executing its
strategic vision for commercial and academic partnerships. She has
played a leading role in transitioning the Company's 3D genomics
platform from development to practical application in R&D.
With over a decade of senior leadership experience in oncology
research, Hazel brings expertise in all phases of drug development,
from target validation to clinical development, driving operational
change to advance disease diagnosis and treatments. Prior to
joining Enhanc3D Genomics as COO in November 20231, Hazel held
various roles within AstraZeneca, including Executive Product
Director of Clinical Data, and Head of Business Planning and
Operations in Oncology R&D. She was also previously Head of
Combination Therapies at Cancer Research UK. Hazel holds a BSc in
Pharmacology and completed her PhD in Biochemistry at the
University of Leeds.
Enhanc3D Genomics has established a genome-wide 3D-genome
mapping technology, GenLink3D™, which provides profound insights
into long-distance gene regulation and disease pathways,
demystifying the non-coding genome. GenLink3D profiles 3D genome
folding at high resolution and over long distances, for all genes
and their enhancers, identifying cell-type specific contacts and
providing complete genome connectivity to disease pathways for the
discovery of novel targets and biomarkers. 3D genomics can identify
novel disease genes, reveal mechanisms of drug action, stratify
patients and more. Enhanc3D Genomics is using this approach to
identify the right target, in the right cell for the right patient,
enabling its commercial and academic partners to both optimally arm
and de-risk their drug discovery process.
Dr Chris Torrance, Chairman of the Board of Directors,
Enhanc3D Genomics, said: “We're thrilled to officially appoint
Hazel as CEO. Her guidance as COO and interim CEO has been
instrumental in driving Enhanc3D Genomics’ global operations,
forming new connections and developing existing strategic
partnerships. On behalf of the Board, I congratulate Hazel and look
forward to continuing to work with her during this exciting phase
for the Company.”
Dr Hazel Jones, Chief Executive Officer, Enhanc3D Genomics,
added: “My time as COO and interim CEO has been highly
rewarding, and I am now honoured and excited to have been appointed
to continue to lead Enhanced Genomics as CEO. I am grateful for the
trust placed in me by the Board and look forward to continuing to
lead the company through our pivotal transition period to full
commercialisation of our 3D genomics platform.”
- Press release (6th November 2023) Enhanc3D Genomics expands
leadership team with the appointment of Hazel Jones as Chief
Operating Officer
For more information please visit: www.enhanc3dgenomics.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240514768468/en/
Zyme Communications Katie Odgaard Tel: +44(0)7787 502 947
Email: katie.odgaard@zymecommunications.com